ProQR's Novel NTCP Drug Candidate Heads to Clinical Trials in Biotech Milestone

Rhea-AI Filing Summary

ProQR Therapeutics has submitted a Clinical Trial Application (CTA) for a Phase 1 study of AX-0810, a novel drug candidate targeting NTCP (sodium taurocholate co-transporting polypeptide). This regulatory filing marks a significant milestone in the company's drug development pipeline.

Key points from the Form 6-K filing:

• The announcement was made via press release on June 26, 2025
• The filing includes a press release as Exhibit 99.1
• The information is being furnished under Form 6-K and is not considered "filed" under Section 18 of the Securities Exchange Act
• The document was signed by Dennis Hom, Chief Financial Officer

This development represents a strategic advancement in ProQR's clinical program, potentially expanding their therapeutic portfolio. The CTA submission indicates the company is progressing toward clinical trials for AX-0810, which could have implications for investors following ProQR's drug development pipeline.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

For the month of June 2025

 

Commission File Number: 001-36622

 

PROQR THERAPEUTICS N.V.

 

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 

 

 

 

On June 26, 2025, ProQR Therapeutics N.V. (“ProQR”) issued a press release titled “ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information in this Report on Form 6-K, including Exhibit 99.1 attached hereto, of ProQR is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	PROQR THERAPEUTICS N.V.
 	 
Date: June 26, 2025	By:	/s/ Dennis Hom
 	 	Dennis Hom
 	 	Chief Financial Officer

 

 

 

 

INDEX TO EXHIBITS

 

Number	 	Description
 	 	 
99.1	 	Press Release of ProQR Therapeutics N.V. dated June 26, 2025.

 

 

 

FAQ

What regulatory submission did PRQR announce in June 2025?

PRQR announced the submission of a Clinical Trial Application (CTA) for a Phase 1 study of their drug candidate AX-0810, which targets NTCP. This announcement was made via press release on June 26, 2025.

Who is the current CFO of PRQR as of June 2025?

According to the Form 6-K filing, Dennis Hom is serving as the Chief Financial Officer of ProQR Therapeutics N.V., as evidenced by his signature on the document dated June 26, 2025.

What type of annual reports does PRQR file with the SEC?

According to the filing, PRQR files annual reports under Form 20-F, as indicated by the checkbox marked 'x' next to Form 20-F in the document.

Where is PRQR's principal executive office located?

ProQR Therapeutics N.V.'s principal executive office is located at Zernikedreef 9, 2333 CK Leiden, The Netherlands, with telephone number +31 88 166 7000.